European regulatory framework on the use and development of pharmaceuticals and radiopharmaceuticals for pediatrics

Hellenic Journal of Nuclear Medicine

Volumn 14, Issue 1, 2011, Pages 43-48

  Mensonides Harsema, Marguérite M ^a   Otte, Andreas ^b,c  

^a University of Applied Sciences ^*

^b WHL Graduate School of Economics   (Germany)

^c OFFENBURG UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Drug approval; European regulations; Evidence based medicine; Pediatrics; Radiopharmaceuticals

Indexed keywords

HERBACEOUS AGENT; IBRITUMOMAB TIUXETAN; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; RUBIDIUM 82; TOSITUMOMAB I 131;

ADVISORY COMMITTEE; ARTHRITIS; B LYMPHOCYTE; CHILDHOOD DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; DIAGNOSTIC TEST; DRUG APPROVAL; DRUG COST; DRUG INFORMATION; DRUG PROGRAM; DRUG SAFETY; DRUG SYNTHESIS; DRUG USE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; LARGE CELL LYMPHOMA; MEDICAL RESEARCH; MEDICINAL PLANT; PEDIATRIC ADVANCED LIFE SUPPORT; PEDIATRICS; PHARMACY; PROGRAM DEVELOPMENT; RARE DISEASE; SHORT SURVEY; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

DRUG DISCOVERY; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; PEDIATRICS; RADIOPHARMACEUTICALS; SOCIAL CONTROL, FORMAL;

EID: 79955370770     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (47)

1. http://www.ema.europa.eu/docs/en-GB/document-library/Report/2010/04/ WC500089445.pdf; accessed 14 September 2010.
2. Bickerstaff R. Pediatric Workshop EFPIA 2003; http://bio.sharepointsite. net/policy/pre-clinical/Shared%20Documents/ BioSafe%20General%20Membership%20Meeting%202009/ Pediatric%20Investigational%20Plans%20and%20Case%20Studies.pdf; accessed 15 September 2010.
3. EURORDIS position paper on the proposal for a regulation on medicinal products for paediatric use: "Medicines for children: Better, more and faster" http://www.eurordis.org/IMG/pdf/eurordis-position-medicines- children-31jan05.pdf; accessed 15 September 2010.
4. Ceci A, Felisi M, Baiardi P et al. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. Eur J Clin Pharmacol 2006; 62: 947-52. (Pubitemid 44657629)
5. Rodriguez WJ, Roberts R, Murphy D. Current regulatory policies regarding pediatric indications and exclusivity. J Pediatr Gastroenterol Nutr 2003; 37: S40-5.
6. Rodriguez W, Selen A, Avant D et al. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 2008; 121: 530-9.
7. Guideline on conduct of pharmacovigilance for medicines used by the pediatric population, EMEA, Aug 2005; http://www.emea.int.pdfs/human/phvwp/ 23591005en.pdf ; accessed 14 September 2010.
8. EMEA Reflection paper: formulations of choice for the pediatric population.EMEA/CHMP/PEG/194810/2005; http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003782.pdf; accessed 15 September 2010.
9. CHMP Draft Guideline on the role of pharmacokinetics in the development of medicinal products in the pediatric population. EMEA/CHMP/EWP/147013/2004. February 2005; http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003066.pdf; accessed 15 September 2010.
10. Cydzik I, Kilian K, Hagen M. Use of radionuclide therapy: actual clinical applications. Oral presentation at the Postgraduate Certified Course Radiopharmaceutical Chemistry/ Radiopharmacy, Zurich, 15 February 2008; http://www.radiochem.pharma.ethz.ch/docs/group-10; accessed 15 September 2010.
11. Otte A, Rose C, Zaehringer A, Maier-Lenz H. Neue klinische Technologien in der Arzneimittelentwicklung. Internist 2008; 49: 232-7.
12. Isitt, V. Legal and ethical problems peculiar to pediatric clinical trials. Part 1: Legal issues. The Regulatory Review 2002; 5: 12-6.
13. EU Directive 2001/20/EC: Implementation of GCP in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities, 2001, L121/34-44; http://www.eortc.be/Services/Doc/clinical-EU- directive-04-April-01.pdf; accessed 15 September 2010.
14. Vassal G. Will children with cancer benefit from the new European Paediatric Medicines Regulation? Eur J Cancer 2009; 45: 1535-46.
15. Cooney-Qualter E, Krailo M, Angiolillo A et al. A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non-Hodgkin's Lymphoma: A Children's Oncology Group Study. Clin Cancer Res 2007; 13: 5652-60.
16. Otte A and Dierckx RA. Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk? Nucl Med Comm 2005; 26: 1045-7.
17. Regulation (EC) No 1901/2006 on medicinal products for paediatric use (amending Regulation 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004); http://ec.europa.eu/health/files/eudralex/vol-1/ reg-2006-1901/reg-2006-1901-en.pdf; accessed 15 September 2010.
18. Regulation (EC) No 1902/2006 on medicinal products for paediatric use (amending Regulation (EC) No 1901/2006)]; http://www.mhra.gov.uk/home/idcplg? ldcService=GET-FILE&dDocName=con2025616&RevisionSelectionMethod=Latest; accessed 15 September 2010.
19. EMEA© Frequently asked questions on regulatory aspects of Regulations (EC) No 1901/2006 and Regulation (EC) No 1902/2006. Doc. Ref. EMEA/520085/ 2006 (Version 2.0); http://www.ema.europa.eu/docs/en-GB/document- library/Other/2009/09/WC500003768.pdf; accessed 15 September 2010.
20. Cordis homepage: http://cordis.europa.eu/fp7/home-en.html; accessed 14 September 2010.
21. EU Community database for clinical trials (EudraCT) homepage: http://www.eudra.org/emea.html; accessed 14 September 2010.
22. European Union Drug Regulating Authorities Pharmaceutical Database (EudraPharm), homepage: http://eudrapharm.eu/eudrapharm/eudrapharm-help.do; accessed 14 September 2010.
23. http://www.ema.europa.eu/ema/index.jsp?curl=pages/about-us/general/ general-content-000124.jsp&murl=menus/about-us/about-us.jsp&mid= WC0b01ac0580028e9e; accessed 14 September 2010.
24. http://www.ema.europa.eu/ema/index.jsp?curl=pagesabout-us/general/ general-content-000095jsp&murl=menus/about-us/about-us.jsp&mid= WC0b01ac0580028c7a; accessed 14 September 2010.
25. http://conventions.coe.int/treaty/en/treaties/html/164.htm; accessed at 14 September 2010.
26. Official Journal of the European Union; 24.9.2008, pC243/1-C243/12; http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:243:0001:0012: EN:PDF; accessed 14 September 2010.
27. Frequently asked questions; http://www.ema.europa.eu/ema/index.jsp?curl= pages/regulation/q-and-a/q-and-a-detail-000015.jsp&mid= WC0b01ac0580025b8e&murl=menus/regutations/regulations.jsp&jsenabled= true; accessed 14 September 2010.
28. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/ general-content-000413.jsp&murl=menus/regulations/regulations.jsp&mid= WC0b01ac0580025ea2; accessed 14 September 2010.
29. Revised priority list for studies into off-patent paediatric medicinal products for the 6th call 2012 of the 7th Framework Programme of the European Commission from the 26 July 2010; doc.nr. EMA/480235/2010; http://www.ema. europa.eu/docs/en-GB/document-library/Other/2010/06/WC500093996.pdf; accessed 14 September 2010.
30. http://www.peddose.net/cms/website.php; accessed 14 September 2010.
31. Verbruggen A, Coenen HH, Deverre JR et al. Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging 2008 DOI 10.1007/s00259-008-0853-7;https://www.eanm.org/scientific- info/guidelines/-radio-phct-259-853.pdf; accessed at 14 September 2010.
32. https://www.eanm.org/scientific-info/guidelines/guidelines-intro.php? navId=54&PHPSESSID=34cdf87b65eb6f0dca7b9a5039ca925; accessed at 14 September 2010.
33. http://www.bfs.de/de/bfs/forschung; accessed 14 September 2010.
34. http://www.inserm.fr/index.php; accessed 14 September 2010.
35. httpy/www.ugent.be/nl/onderzoek/financieringkaderprogramma/7kp/portfolio. htm; accessed 14 September 2010.
36. http://www.uni-wuerzburg.de/en/sonstiges/meldungen/detail/artikel/ langzeitef/; accessed 14 September 2010.
37. http://www.eibir.org/cms/website.php?id=/en/projects/eu-projects/ peddose-net.htm; accessed 14 September 2010.
38. EMEA-000488-PIP01-08; http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicinespips/EMEA-000488-PIP01-08/pip-000221jsp&murl=menus/medicines/ medicines.jsp&mid=WC0b01ac058001d129); accessed 14 September 2010.
39. EMEA-000308-PIP01-08;http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/pips/EMEA-000308-PIP01-08/pip-000126.jsp&mid= WC0b01ac058001d129&murl=menus/medicines/medicines.jsp&jsenabled=true; accessed 14 September 2010.
40. Otte A, Wiele vd C, Dierckx RA. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step. Nucl Med Comm 2009; 30: 5-15.
41. Gabriel A, Hanel M, Wehmeyer J, Griesinger F. Advantages in cost effectiveness of Zevalin radioimmunotherapy vs. rituximab immunotherapy inpatients with relapsed or refractory follicular non-Hodgkin's lymphoma. Onkologie 2005; 28(suppl 3): 236.
42. Otte A. Does health economics have an impact on non-Hodgkin's lymphoma patients' options? Nucl Med Comm 2008; 29: 748-50.
43. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500002926.pdf; accessed 14 September 2010.
44. http://www.fda.gov/RegulatoryInformation/Guidances/ucm129476.htm; accessed 14 September 2010.
45. Murphy, D. Europe & USA: Interactions on Pediatric Clinical Trials. Oral Presentation 2008; http://www.fda.gov/ohrms/dockets/ac/08/slides/2008- 4352s1-06-FDA-Murphy.ppt; accessed 15 September 2010.
46. Sam T. Regulatory requirements for the development of medicinal products for pediatric use. Presentation at WHO/FIP-sponsored workshop in Capetown (SA), April 2007; http://www.who.int/prequal/trainingresources/pq-pres/TrainingZA- April07/RegRequire.ppt; accessed 15 September 2010.
47. http://www.ema.europa.eu/ema/index.jsp?curl= pages%2Fmedicines%2Flanding%2Fpip-search.jsp&murl= menus%2Fmedicines%2Fmedicines.jsp&mid=WC0b01ac058001d129& searchkwByEnter=false&alreadyLoaded=true&startLetter= View+all&keyword=Enter+keywords&searchType=Invented+name& taxonomyPath=&treeNumber=&jsenabled=true; accessed 14 September 2010.